About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker CPIX · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Sep 2, 2026Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT05571059 · Idiopathic Pulmonary Fibrosis
Ifetroban Sodium, Placebo
CPIX
Cumberland Pharmaceuticals
Phase 2Recruiting128Jan 2028Registry ↗
Sep 2, 2026Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arte…
NCT02682511 · Scleroderma, Diffuse, Scleroderma, Systemic
Oral Ifetroban, Oral Placebo
CPIX
Cumberland Pharmaceuticals
Phase 2Active, not recruiting34Mar 2026Registry ↗
Mar 17, 2026Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy
NCT03340675 · Duchenne Muscular Dystrophy Cardiomyopathy, Cardiomyopathy,…
Ifetroban, Placebo
CPIX
Cumberland Pharmaceuticals
Phase 2Completed46Mar 6, 2024Registry ↗
Jul 10, 2024Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)
NCT03028350 · Asthma, Aspirin-Induced
Ifetroban Oral Capsule, Placebo Oral Capsule
CPIX
Cumberland Pharmaceuticals
Phase 2Completed54Apr 25, 2023Registry ↗
Jun 24, 2024Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)
NCT02013141 · Gram-Positive Bacterial Infections
Telavancin
CPIX
Cumberland Pharmaceuticals
Phase 1Terminated22Mar 2021Registry ↗
Feb 28, 2024Surgical Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous Ibuprofen
NCT01334957 · Pain
Intravenous ibuprofen
CPIX
Cumberland Pharmaceuticals
Phase 4Completed300Dec 2012Registry ↗
Jul 5, 2023Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous Ibuprofen
NCT01334944 · Pain, Fever
Intravenous ibuprofen
CPIX
Cumberland Pharmaceuticals
Phase 4Completed150Sep 2012Registry ↗
Jul 15, 2022Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemi…
NCT03611010 · Hypercholesterolemia, Dyslipidemias
Atorvastatin injection
CPIX
Cumberland Pharmaceuticals
Phase 2Completed40Feb 17, 2020Registry ↗
Jan 19, 2022Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic…
NCT02802228 · Portal Hypertension, Liver Cirrhosis
Ifetroban, Placebo
CPIX
Cumberland Pharmaceuticals
Phase 2Completed30Jul 17, 2018Registry ↗
Nov 20, 2020Safety and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients
NCT02583399 · Pain, Fever
Ibuprofen
CPIX
Cumberland Pharmaceuticals
Phase 4Completed30Jul 2, 2019Registry ↗
Oct 19, 2020VIBATIV Pregnancy Registry
NCT01130324 · Pregnancy
VIBATIV
CPIX
Cumberland Pharmaceuticals
—Withdrawn0Oct 2020Registry ↗
Feb 17, 2020A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial
NCT02208063 · Bacteremia
Telavancin, Vancomycin
CPIX
Cumberland Pharmaceuticals
Phase 3Terminated121Apr 12, 2018Registry ↗
Jan 16, 2019Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistan…
NCT00124020 · Bacterial Pneumonia
Telavancin, Vancomycin
CPIX
Cumberland Pharmaceuticals
Phase 3Completed771May 2007Registry ↗
Jan 16, 2019Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a F…
NCT00107978 · Staphylococcal Skin Infection
Telavancin, Vancomycin
CPIX
Cumberland Pharmaceuticals
Phase 3Completed1,035May 2006Registry ↗
Jan 16, 2019Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistan…
NCT00107952 · Bacterial Pneumonia
Telavancin, Vancomycin
CPIX
Cumberland Pharmaceuticals
Phase 3Completed761Jul 2007Registry ↗
Jan 16, 2019Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a F…
NCT00091819 · Staphylococcal Skin Infection
Telavancin, Vancomycin
CPIX
Cumberland Pharmaceuticals
Phase 3Completed862Jun 2006Registry ↗
Jan 16, 2019Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin an…
NCT00077675 · Infections, Gram-positive Bacterial
Telavancin, vancomycin or antistaphylococcal penicillin
CPIX
Cumberland Pharmaceuticals
Phase 2Completed201Sep 2004Registry ↗
Jan 16, 2019Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia
NCT00062647 · Gram-Positive Bacterial Infections
Telavancin, Vancomycin, nafcillin, oxacillin, or cloxacillin
CPIX
Cumberland Pharmaceuticals
Phase 2Completed60Aug 2006Registry ↗
Jan 16, 2019Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin an…
NCT00061633 · Infections, Gram-Positive Bacterial, Abscess
Telavancin, Vancomycin or antistaphylococcal penicillin
CPIX
Cumberland Pharmaceuticals
Phase 2Completed169Jan 2004Registry ↗
Jan 15, 2019Telavancin Observational Use Registry (TOUR)
NCT02288234 · Hospital Acquired Bacterial Pneumonia, Complicated Skin and…
Vibativ
CPIX
Cumberland Pharmaceuticals
—Completed1,063Jun 2017Registry ↗
Jan 15, 2019A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin
NCT01238796 · Kidney Diseases, End Stage Renal Disease
telavancin
CPIX
Cumberland Pharmaceuticals
Phase 1Completed45Feb 2011Registry ↗
May 15, 2017Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated R…
NCT02216357 · Aspirin Exacerbated Respiratory Disease (AERD)
Ifetroban, Oral Capsule, Placebo, Oral Capsule
CPIX
Cumberland Pharmaceuticals
Phase 2Completed19Jan 2016Registry ↗
Mar 1, 2017Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients
NCT01436500 · Hepatorenal Syndrome
Ifetroban Injection, Placebo
CPIX
Cumberland Pharmaceuticals
Phase 2Completed55Jun 2015Registry ↗
Nov 7, 2016Safety, Efficacy, and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients
NCT01002573 · Fever
ibuprofen, acetaminophen
CPIX
Cumberland Pharmaceuticals
Phase 3Completed118Jun 2013Registry ↗
Nov 3, 2016Safety and Efficacy of Intravenous Ibuprofen for Treatment of Pain in Pediatric Patients Undergoing…
NCT01332253 · Tonsillectomy
Intravenous ibuprofen, Normal Saline
CPIX
Cumberland Pharmaceuticals
Phase 3Completed161Jul 2012Registry ↗
Jun 23, 2016A Pilot Study to Determine the Efficacy of Intravenous Ibuprofen for Pain Control Following Arthros…
NCT01650519 · Arthroscopic Knee Surgery
IV ibuprofen, IV ketorolac
CPIX
Cumberland Pharmaceuticals
Phase 4Completed51Dec 2012Registry ↗
Jun 22, 2016Trial of Caldolor for Treatment of Pain in Post-Operative Adult Patients
NCT00225732 · Pain
Normal saline as placebo comparator, Intravenous ibuprofen
CPIX
Cumberland Pharmaceuticals
Phase 3Completed319Jan 2008Registry ↗
Mar 14, 2016Efficacy of Intravenous Ibuprofen Compared to Intravenous Ketorolac for Pain Control Following Arth…
NCT01901393 · Pain
IV ibuprofen, Ketorolac
CPIX
Cumberland Pharmaceuticals
Phase 4Completed100Aug 2014Registry ↗
Mar 1, 2016A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) i…
NCT01451411 · Hyponatremia
Conivaptan hydrochloride, Placebo
CPIX
Cumberland Pharmaceuticals
Phase 3Terminated4Jan 2014Registry ↗
Feb 24, 2016Efficacy and Safety of Bisacodyl and Lactulose as a Preparation for Colonoscopy
NCT02123017 · Colonoscopy Preparation
90 grams of Crystalline Lactulose, 135 grams of Crystalline…
CPIX
Cumberland Pharmaceuticals
Phase 2Completed32Aug 2014Registry ↗
Aug 21, 2015Efficacy and Safety Study of Caldolor (IV Ibuprofen) in Hospitalized Adult Orthopedic Patients
NCT00470600 · Pain
Caldolor, Normal Saline
CPIX
Cumberland Pharmaceuticals
Phase 3Completed185Sep 2008Registry ↗
Jun 1, 20152 Regimens of Lactulose for Colonoscopy Preparation in Adults
NCT01887470 · Colonoscopy Preparation
Full dose preparation, Split dose preparation
CPIX
Cumberland Pharmaceuticals
Phase 2Completed55Oct 2013Registry ↗

32 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:03 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances